Debbie Rigby rounds up the latest in research news pertinent to pharmacy
The results of a 6-month multicenter, randomized, double-blind, placebo-controlled clinical trial demonstrate that CS/GS combination therapy was inferior to placebo in terms of reducing joint pain and functional impairment in patients with symptomatic knee OA over 6 months. CS (1,200 mg) plus GS (1,500 mg) or placebo was used in the trial.
Arthritis & Rheumatology 2017;69(1):77–85.
A randomized, double-blind, placebo-controlled clinical trial comparing magnesium oxide capsules to placebo did not show no any difference between-group differences in the severity and duration of nocturnal leg cramps, quality of life, or quality of sleep. Participants took a inorganic granular magnesium complex, composed of magnesium oxide and magnesium oxide monohydrate 865mg, providing 520mg of free elemental Mg2+[magnesium]) or a similar-looking placebo to be taken orally, once daily at bedtime for a period of 4 weeks.
JAMA Intern Med. Published online February 20, 2017.
Post-hoc analysis of the 3 year inhaled Steroid Treatment As Regular Therapy (START) study suggests that treatment recommendations for low dose inhaled corticosteroids for mild asthma should consider both risk reduction and symptoms. In mild recent-onset asthma, once daily, low-dose budesonide decreased severe asthma-related event risk, reduced lung function decline, and improved symptom control similarly across all symptom subgroups.
A systematic review and mixed-treatment comparison analysis of 34 trials (14 464 participants) has concluded that all GLP-1RAs reduced glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) levels. When all GLP-1RAs were compared with each other, no clinically meaningful differences were observed in weight loss, blood pressure reduction or hypoglycaemia risk. Once-weekly exenatide was superior to twice-daily exenatide at lowering HbA1c and FPG levels.